SEQOVA Biotech Insights | May 2026
The approved CAR-T therapies that reshaped haematological oncology over the past decade were all made from the patient’s own cells. Autologous production is what made the clinical results possible. It is also what makes the therapy structurally difficult to scale, expensive to deliver, and inaccessible to patients who deteriorate before their cells can be processed.
The solution — manufacturing CAR-T products from donor cells — has been understood for years. Executing it consistently, safely, and at commercial scale has proved harder. That challenge is now being addressed with increasing sophistication in China, at a pace and volume that European licensing teams have largely not tracked. The clinical data is maturing. The assets exist. The window to access them at current valuations is not permanent.
The Ceiling Autologous Cannot Break
The clinical case for autologous CAR-T is established. CD19-directed therapies have produced durable remissions in patients with relapsed or refractory B-cell malignancies where no other options remained. BCMA-directed therapies have done the same in multiple myeloma. The commercial case is more complicated.
Autologous manufacturing requires individual patient leukapheresis, centralised GMP production, cold-chain logistics, and vein-to-vein timelines that routinely run four to eight weeks. Each batch is unique. Failure rates and out-of-specification events are material. Qualified treatment centres are few. The per-patient cost in most Western markets sits between $350,000 and $500,000.
These are not problems that incremental engineering will fully solve. They are structural features of a model built around individual patient material. Allogeneic CAR-T is a different model.
What Allogeneic Changes — and What It Still Has to Prove
Allogeneic, or off-the-shelf, CAR-T uses T cells derived from healthy donors — or from umbilical cord blood or iPSC sources — to produce standardised batches that can be stored, shipped, and administered without patient-specific manufacturing. The theoretical advantages are significant: faster availability, greater manufacturing consistency, and the potential for substantially lower cost at scale.
The practical challenges have been equally significant. Donor T cells carry risk of graft-versus-host disease. They are recognised as foreign by the recipient’s immune system and cleared, limiting persistence. Early allogeneic programmes produced shorter-lived responses than their autologous counterparts, and that gap has not been fully closed.
The engineering response — targeted gene edits to remove TCR expression and reduce HLA mismatch immunogenicity — is now mature enough to support late-stage clinical programmes. Several candidates are in Phase II. The question is no longer whether allogeneic CAR-T is feasible. It is which platforms have solved the persistence problem well enough to deliver durable responses at scale.
China’s Contribution Is Not Incremental
China’s role in CAR-T has been framed largely in terms of volume: more clinical trials than any other country, consistently, since around 2017. That framing understates what has actually been built.
Chinese developers have made specific engineering choices that distinguish their allogeneic programmes from dominant Western approaches. The most notable is the use of umbilical cord blood as a T-cell source. Cord blood T cells are immunologically naive — less differentiated, with better expansion capacity and potentially more durable persistence than peripheral blood-derived cells from adult donors. Pairing naive T-cell biology with targeted editing for GvHD prevention represents a distinct approach to the persistence problem, not a variation on existing methods.
Chinese programmes have also accumulated clinical data in autoimmune indications — particularly systemic lupus erythematosus — at a scale and speed that Western developers are only beginning to approach. That data is starting to reach a stage where serious due diligence is feasible. Much of it has not yet been presented at Western congresses.
The Autoimmune Signal and What It Means for Market Size
CAR-T’s mechanism — depleting B cells through targeted killing — applies not only to malignant cells but to the autoreactive B cells that drive autoimmune disease. In SLE, cohorts treated with CD19-directed CAR-T have shown deep B-cell depletion, significant reductions in autoantibodies, and sustained clinical remissions after a single infusion — outcomes that stand in stark contrast to the incremental benefit most existing biologics provide.
These are early results, and the field is appropriately cautious. But they are compelling enough to have shifted the investment thesis for several major developers. Bristol Myers Squibb, Kyverna Therapeutics, and others have active programmes in lupus and related conditions. The addressable population in autoimmunity is orders of magnitude larger than in haematological oncology.
If allogeneic CAR-T can deliver comparable efficacy at lower cost and with outpatient-compatible logistics, the market case is not incremental. It is transformative. Chinese clinical teams have been building evidence in this space longer than Western awareness reflects.
The Licensing Window
The pattern will be recognisable to anyone who has watched the complex generics space evolve. A cohort of Chinese developers has accumulated genuine scientific capability, generated clinical evidence, and reached a point where Western partnerships would accelerate development — but has not yet built the BD infrastructure to access those partnerships systematically.
The execution gap in innovative assets mirrors the one in complex generics: regulatory pathway translation, CMC documentation to Western standards, IP freedom-to-operate in EU and US jurisdictions, term-sheet literacy. These are solvable problems. They require specific translation work, and that work takes time.
What is less manageable is timing. The allogeneic CAR-T assets that are visible but not yet fully shopped will not remain that way. European companies building these relationships now — working through the clinical data, assessing manufacturing platforms, mapping the regulatory distance to EMA — will access these programmes at materially better terms than those who wait until the assets are widely known.
The tier-one Chinese names are already partnered. The allogeneic CAR-T story, particularly in autoimmunity, is being written one tier below. That is where the valuation gap is.
SEQOVA Biotech Insights covers pharmaceutical licensing opportunities at the China–Europe interface, with a focus on assets and platforms that haven’t yet found their Western partner.